Esperion secures additional commercial, Medicare formulary coverage for NEXLETOL

Esperion announced that NEXLETOL and NEXLIZET have achieved additional coverage on national and large regional formularies since the U.S. Food and Drug Administration’s approval of the expanded indications, increasing total coverage to more than 136 million commercially insured lives and 34 million Medicare lives. Additionally, many payers have accelerated alignment of utilization management criteria since the FDA approval of the expanded indications to the new labels.